Silence Therapeutics (NASDAQ:SLN) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research report released on Thursday, Benzinga reports. HC Wainwright currently has a $75.00 price objective on the stock.

Several other equities research analysts also recently commented on SLN. Morgan Stanley reaffirmed an overweight rating and set a $45.00 price objective on shares of Silence Therapeutics in a report on Monday, April 22nd. Chardan Capital restated a buy rating and set a $42.00 price target on shares of Silence Therapeutics in a research note on Friday, May 17th.

Silence Therapeutics Price Performance

Silence Therapeutics stock opened at $19.00 on Thursday. The firm has a 50 day moving average price of $21.15 and a 200-day moving average price of $20.99. Silence Therapeutics has a twelve month low of $4.84 and a twelve month high of $27.72. The company has a market capitalization of $568.67 million, a P/E ratio of -16.38 and a beta of 1.34.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings data on Thursday, May 16th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.18. The business had revenue of $15.73 million during the quarter, compared to analyst estimates of $4.53 million. Silence Therapeutics had a negative return on equity of 79.90% and a negative net margin of 131.44%. Equities analysts expect that Silence Therapeutics will post -1.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SLN. Redmile Group LLC purchased a new stake in shares of Silence Therapeutics in the first quarter worth $43,798,000. Vivo Capital LLC increased its stake in Silence Therapeutics by 116.7% in the 1st quarter. Vivo Capital LLC now owns 1,105,454 shares of the company’s stock worth $23,878,000 after acquiring an additional 595,250 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Silence Therapeutics in the 1st quarter valued at about $13,575,000. Lynx1 Capital Management LP boosted its position in shares of Silence Therapeutics by 123.4% during the 1st quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock valued at $11,375,000 after acquiring an additional 290,855 shares during the last quarter. Finally, Parkman Healthcare Partners LLC grew its holdings in shares of Silence Therapeutics by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,063 shares in the last quarter. 98.73% of the stock is owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.